These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 665130)

  • 21. Evaluation of coagulation equilibrium at baseline and during factor VIII and factor IX replacement in haemophiliacs.
    Négrier C; Menart C; Attali O; Petit PY; Lienhart A; Dechavanne M; Ingerslev J
    Blood Coagul Fibrinolysis; 1998 Mar; 9 Suppl 1():S135-41. PubMed ID: 9819045
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Preparation and clinical use of factor IX concentrate PPSB according to Soulier.
    Haanen C; McShine RL; Kunst A
    Vox Sang; 1969 Apr; 16(4):398-411. PubMed ID: 5800593
    [No Abstract]   [Full Text] [Related]  

  • 23. Safety and efficacy of monoclonal antibody purified factor IX concentrate in previously untreated patients with hemophilia B.
    Shapiro AD; Ragni MV; Lusher JM; Culbert S; Koerper MA; Bergman GE; Hannan MM
    Thromb Haemost; 1996 Jan; 75(1):30-5. PubMed ID: 8713776
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In vivo recovery of factor VIII and factor IX: intra- and interindividual variance in a clinical setting.
    Björkman S; Folkesson A; Berntorp E
    Haemophilia; 2007 Jan; 13(1):2-8. PubMed ID: 17212717
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety and efficacy of purified factor IX concentrate and antifibrinolytic agents for dental extractions in hemophilia B.
    Djulbegovic B; Marasa M; Pesto A; Kushner GM; Hadley T; Joseph G; Goldsmith G
    Am J Hematol; 1996 Feb; 51(2):168-70. PubMed ID: 8579061
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Haemophilia B Leyden in Greece.
    Mandalaki T; Louizou C; Dimitriadou C; Briët E
    Thromb Haemost; 1986 Dec; 56(3):340-2. PubMed ID: 3563965
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical experience of a new monoclonal antibody purified factor IX: half-life, recovery, and safety in patients with hemophilia B.
    Kim HC; McMillan CW; White GC; Bergman GE; Saidi P
    Semin Hematol; 1990 Apr; 27(2 Suppl 2):30-5. PubMed ID: 2094957
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Preparation of factor IX concentrate with the use of DEAE-cellulose and its therapeutic results].
    Uszyński L; Poszwiński P
    Acta Haematol Pol; 1971; 2(2):109-14. PubMed ID: 5170671
    [No Abstract]   [Full Text] [Related]  

  • 29. Recombinant factor IX.
    White GC; Beebe A; Nielsen B
    Thromb Haemost; 1997 Jul; 78(1):261-5. PubMed ID: 9198163
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In vitro characterization of high purity factor IX concentrates for the treatment of hemophilia B.
    Limentani SA; Gowell KP; Deitcher SR
    Thromb Haemost; 1995 Apr; 73(4):584-91. PubMed ID: 7495063
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Use of 2 preparations of factor IX concentrate in the treatment of a patient with hemophilia B].
    den Ottolander GJ
    Ned Tijdschr Geneeskd; 1972 Jul; 116(30):1278-82. PubMed ID: 5041298
    [No Abstract]   [Full Text] [Related]  

  • 32. No activation of the common pathway of the coagulation cascade after a highly purified factor IX concentrate.
    Mannucci PM; Bauer KA; Gringeri A; Barzegar S; Santagostino E; Tradati FC; Rosenberg RD
    Br J Haematol; 1991 Dec; 79(4):606-11. PubMed ID: 1772782
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Myocardial infarction during factor IX infusion in hemophilia B: case report and review of the literature.
    Najaf SM; Malik A; Quraishi AU; Kazmi K; Kakepoto GN
    Ann Hematol; 2004 Sep; 83(9):604-7. PubMed ID: 15205916
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Biochemical and in vivo properties of high purity factor IX concentrates.
    Berntorp E; Björkman S; Carlsson M; Lethagen S; Nilsson IM
    Thromb Haemost; 1993 Nov; 70(5):768-73. PubMed ID: 8128433
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Thrombin formation in factor IX concentrates and FEIBA (factor eight inhibitor bypassing activity) (proceedings)].
    Hofmann V; Ermanni M; Straub PW
    Schweiz Med Wochenschr; 1978 Oct; 108(41):1600. PubMed ID: 694497
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical evaluation of recombinant factor IX.
    White G; Shapiro A; Ragni M; Garzone P; Goodfellow J; Tubridy K; Courter S
    Semin Hematol; 1998 Apr; 35(2 Suppl 2):33-8. PubMed ID: 9565165
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Human coagulation factor IX: assessment of thrombogenicity in animal models and viral safety.
    Herring SW; Abildgaard C; Shitanishi KT; Harrison J; Gendler S; Heldebrant CM
    J Lab Clin Med; 1993 Mar; 121(3):394-405. PubMed ID: 8445288
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Rituximab in the treatment of alloimmune factor VIII and IX antibodies in two children with severe haemophilia.
    Mathias M; Khair K; Hann I; Liesner R
    Br J Haematol; 2004 May; 125(3):366-8. PubMed ID: 15086418
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Prevention of severe haemophilia B with a factor IX concentrate (author's transl)].
    Ludwig E; Lechner K
    Dtsch Med Wochenschr; 1974 Jun; 99(25):1355-61. PubMed ID: 4836072
    [No Abstract]   [Full Text] [Related]  

  • 40. [A controlled study of long-term treatment of haemophilia B on an out-patient basis (author's transl)].
    Schimpf K; Baumann P
    Dtsch Med Wochenschr; 1976 Feb; 101(7):233-8. PubMed ID: 1248406
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.